Tuesday, October 22, 2019
Home Authors Posts by Editor / Curator

Editor / Curator

136 POSTS 0 COMMENTS
Dyadic, Biotech Stock Review
Biotech News

Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

Editor / Curator -
Dyadic
Biotech News

Investor Presentation Slides From Dyadic (DYA) $6.40.

Editor / Curator -
Tue Nature, Biotch Stock Review
Biotech News

True Nature Holding (TNTY) Announces New Board Member and CEO.

Editor / Curator -
Biotech News

Dawson James Securities Announces 5th Annual Small Cap Growth Conference.

Editor / Curator -
Steven Boyd, Armistice Capital, Biotech Stock Review
Biotech News

Armistice Capital Voting on AYTU (AYTU) and Innovus (INNV) Merger.

Editor / Curator -
internet stock review, booster
eCommerce

Booster Raises $56 million to Deliver Fuel Directly to Cars.

Editor / Curator -
Internet Stock Review, HCN Navigator, Hotel Communications Network
Internet News

HCN Navigator Driving ‘Profit at First Touch’ for Hotels.

Editor / Curator -
biotech stock review
Biotech News

Innovus (INNV) Gains 75% in Past Week.

Editor / Curator -
aytu, innovus
Internet News

AYTU (ATYU) ‘Team’ Letter on Innovus (INNV) Acquisition.

Editor / Curator -
Institutional Analyst Newsletter

Adding Accelerize (ACLZ) $0.05 to Watch List.

Editor / Curator -
123...14Page 1 of 14

Latest article

Dyadic, Biotech Stock Review

Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

Biotech News Editor / Curator -
Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
Dyadic

Investor Presentation Slides From Dyadic (DYA) $6.40.

Biotech News Editor / Curator -
Really, How Do We Do It? Live Short Term Chart
Tue Nature, Biotch Stock Review

True Nature Holding (TNTY) Announces New Board Member and CEO.

Biotech News Editor / Curator -
Lawrence M. Diamond Joins True Nature Holding, Inc. in Board, CEO Roles, Brings Career Telehealth, Healthcare and Technology Focus
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.